Aspira Women's Health

Aspira Women's Health is a public company focused on transforming the clinical management of ovarian adnexal masses through its AI-driven multivariate index assays (MIAs). Its core achievement is the commercial OvaSuite portfolio, including Ova1, Overa, and OvaWatch, which have demonstrated superior sensitivity over CA-125 alone and are supported by over 200,000 tests performed. The company's strategy centers on expanding adoption of its tests within established clinical guidelines, leveraging its growing dataset to refine its algorithms, and pursuing new biomarker discoveries to solidify its leadership in gynecologic diagnostics.

A proprietary, AI-driven bioinformatics platform that analyzes multiple serum biomarkers, patient demographics, and clinical data to generate personalized risk scores for ovarian cancer in women with adnexal masses.

Competes primarily against the standard of care (ultrasound + CA-125) and the ROMA test. Differentiates with superior sensitivity data, a full product suite for both surgical and monitoring pathways, and a proprietary AI platform fueled by over 200,000 tests. Long-term competition may come from advanced imaging AI and liquid biopsy technologies.